OR WAIT 15 SECS
Jill Wechsler is BioPharm International's Washington Editor, jillwechsler7@gmail.com.
Jill Wechsler FDA explains its plan for moving most biologics under the authority of CDER. But a big question remains: What will the change do to approval times?
Related Content: